[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Non-Insulin Therapies for Diabetes Market Report 2018

March 2018 | 107 pages | ID: U9F213F8D6AEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Non-Insulin Therapies for Diabetes market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Non-Insulin Therapies for Diabetes in these regions, from 2013 to 2025 (forecast).
United States Non-Insulin Therapies for Diabetes market competition by top manufacturers/players, with Non-Insulin Therapies for Diabetes sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • GSK
  • Eli Lilly
  • Sumitomo Dainippon Pharma
  • Intarcia Therapeutics
  • Servier
  • Jiangsu Hansoh Pharmaceutical
  • Novo Nordisk
  • Emisphere
  • Uni-Bio Science Group
  • Takeda
  • 3SBio
  • Merck
  • Dong-A Pharmaceutical
  • Luye Pharma Group
  • Eurofarma
  • Geropharm
  • Alkem Labs
  • SatRx
  • Pfizer
  • Jiangsu Hengrui Medicine
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Alpha-glucosidase Inhibitors
  • Amylin Agonists
  • Biguanides
  • Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  • Glinides / Meglitinides
  • GLP-1 Analogs / GLP-1 Agonists
  • Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  • Sulfonylureas
  • Thiazolidinediones
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Hospital Pharmacy
  • Retail Pharmacies
  • Online Pharmacy
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Non-Insulin Therapies for Diabetes Market Report 2018

1 NON-INSULIN THERAPIES FOR DIABETES OVERVIEW

1.1 Product Overview and Scope of Non-Insulin Therapies for Diabetes
1.2 Classification of Non-Insulin Therapies for Diabetes by Product Category
  1.2.1 United States Non-Insulin Therapies for Diabetes Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Non-Insulin Therapies for Diabetes Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 Alpha-glucosidase Inhibitors
  1.2.4 Amylin Agonists
  1.2.5 Biguanides
  1.2.6 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  1.2.7 Glinides / Meglitinides
  1.2.8 GLP-1 Analogs / GLP-1 Agonists
  1.2.9 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  1.2.10 Sulfonylureas
  1.2.11 Thiazolidinediones
  1.2.12 Others
1.3 United States Non-Insulin Therapies for Diabetes Market by Application/End Users
  1.3.1 United States Non-Insulin Therapies for Diabetes Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Hospital Pharmacy
  1.3.3 Retail Pharmacies
  1.3.4 Online Pharmacy
  1.3.5 Others
1.4 United States Non-Insulin Therapies for Diabetes Market by Region
  1.4.1 United States Non-Insulin Therapies for Diabetes Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Non-Insulin Therapies for Diabetes Status and Prospect (2013-2025)
  1.4.3 Southwest Non-Insulin Therapies for Diabetes Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Non-Insulin Therapies for Diabetes Status and Prospect (2013-2025)
  1.4.5 New England Non-Insulin Therapies for Diabetes Status and Prospect (2013-2025)
  1.4.6 The South Non-Insulin Therapies for Diabetes Status and Prospect (2013-2025)
  1.4.7 The Midwest Non-Insulin Therapies for Diabetes Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Non-Insulin Therapies for Diabetes (2013-2025)
  1.5.1 United States Non-Insulin Therapies for Diabetes Sales and Growth Rate (2013-2025)
  1.5.2 United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2013-2025)

2 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Non-Insulin Therapies for Diabetes Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Non-Insulin Therapies for Diabetes Average Price by Players/Suppliers (2013-2018)
2.4 United States Non-Insulin Therapies for Diabetes Market Competitive Situation and Trends
  2.4.1 United States Non-Insulin Therapies for Diabetes Market Concentration Rate
  2.4.2 United States Non-Insulin Therapies for Diabetes Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Non-Insulin Therapies for Diabetes Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Region (2013-2018)
3.2 United States Non-Insulin Therapies for Diabetes Revenue and Market Share by Region (2013-2018)
3.3 United States Non-Insulin Therapies for Diabetes Price by Region (2013-2018)

4 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2013-2018)
4.3 United States Non-Insulin Therapies for Diabetes Price by Type (2013-2018)
4.4 United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Type (2013-2018)

5 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Application (2013-2018)
5.2 United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 GSK
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Eli Lilly
  6.2.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Sumitomo Dainippon Pharma
  6.3.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Intarcia Therapeutics
  6.4.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Servier
  6.5.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Jiangsu Hansoh Pharmaceutical
  6.6.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Novo Nordisk
  6.7.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Emisphere
  6.8.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Uni-Bio Science Group
  6.9.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 Takeda
  6.10.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Takeda Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 3SBio
6.12 Merck
6.13 Dong-A Pharmaceutical
6.14 Luye Pharma Group
6.15 Eurofarma
6.16 Geropharm
6.17 Alkem Labs
6.18 SatRx
6.19 Pfizer
6.20 Jiangsu Hengrui Medicine

7 NON-INSULIN THERAPIES FOR DIABETES MANUFACTURING COST ANALYSIS

7.1 Non-Insulin Therapies for Diabetes Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Non-Insulin Therapies for Diabetes Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Non-Insulin Therapies for Diabetes Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Non-Insulin Therapies for Diabetes Sales Volume Forecast by Type (2018-2025)
11.3 United States Non-Insulin Therapies for Diabetes Sales Volume Forecast by Application (2018-2025)
11.4 United States Non-Insulin Therapies for Diabetes Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Non-Insulin Therapies for Diabetes
Figure United States Non-Insulin Therapies for Diabetes Market Size (K Units) by Type (2013-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume Market Share by Type (Product Category) in 2017
Figure Alpha-glucosidase Inhibitors Product Picture
Figure Amylin Agonists Product Picture
Figure Biguanides Product Picture
Figure Dipeptidyl Peptidase-4 (DPP4) Inhibitors Product Picture
Figure Glinides / Meglitinides Product Picture
Figure GLP-1 Analogs / GLP-1 Agonists Product Picture
Figure Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Product Picture
Figure Sulfonylureas Product Picture
Figure Thiazolidinediones Product Picture
Figure Others Product Picture
Figure United States Non-Insulin Therapies for Diabetes Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Non-Insulin Therapies for Diabetes by Application in 2017
Figure Hospital Pharmacy Examples
Table Key Downstream Customer in Hospital Pharmacy
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure Online Pharmacy Examples
Table Key Downstream Customer in Online Pharmacy
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Non-Insulin Therapies for Diabetes Market Size (Million USD) by Region (2013-2025)
Figure The West Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales (K Units) and Growth Rate (2013-2025)
Figure United States Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Non-Insulin Therapies for Diabetes Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Non-Insulin Therapies for Diabetes Sales Share by Players/Suppliers
Figure 2017 United States Non-Insulin Therapies for Diabetes Sales Share by Players/Suppliers
Figure United States Non-Insulin Therapies for Diabetes Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Non-Insulin Therapies for Diabetes Revenue Share by Players/Suppliers
Figure 2017 United States Non-Insulin Therapies for Diabetes Revenue Share by Players/Suppliers
Table United States Market Non-Insulin Therapies for Diabetes Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Non-Insulin Therapies for Diabetes Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Non-Insulin Therapies for Diabetes Market Share of Top 3 Players/Suppliers
Figure United States Non-Insulin Therapies for Diabetes Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Non-Insulin Therapies for Diabetes Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Non-Insulin Therapies for Diabetes Product Category
Table United States Non-Insulin Therapies for Diabetes Sales (K Units) by Region (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales Share by Region (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Share by Region (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Region in 2017
Table United States Non-Insulin Therapies for Diabetes Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Revenue Share by Region (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Revenue Market Share by Region (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Revenue Market Share by Region in 2017
Table United States Non-Insulin Therapies for Diabetes Price (USD/Unit) by Region (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales (K Units) by Type (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales Share by Type (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Share by Type (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Type in 2017
Table United States Non-Insulin Therapies for Diabetes Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Non-Insulin Therapies for Diabetes by Type (2013-2018)
Figure Revenue Market Share of Non-Insulin Therapies for Diabetes by Type in 2017
Table United States Non-Insulin Therapies for Diabetes Price (USD/Unit) by Types (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Type (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales (K Units) by Application (2013-2018)
Table United States Non-Insulin Therapies for Diabetes Sales Market Share by Application (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Application (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Application in 2017
Table United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2013-2018)
Figure United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2013-2018)
Table GSK Basic Information List
Table GSK Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure GSK Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure GSK Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure GSK Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Eli Lilly Basic Information List
Table Eli Lilly Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Eli Lilly Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Eli Lilly Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Eli Lilly Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Sumitomo Dainippon Pharma Basic Information List
Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Intarcia Therapeutics Basic Information List
Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Servier Basic Information List
Table Servier Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Servier Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Servier Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Servier Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Jiangsu Hansoh Pharmaceutical Basic Information List
Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Novo Nordisk Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Novo Nordisk Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Novo Nordisk Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Emisphere Basic Information List
Table Emisphere Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Emisphere Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Emisphere Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Emisphere Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Uni-Bio Science Group Basic Information List
Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table Takeda Basic Information List
Table Takeda Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Takeda Non-Insulin Therapies for Diabetes Sales Growth Rate (2013-2018)
Figure Takeda Non-Insulin Therapies for Diabetes Sales Market Share in United States (2013-2018)
Figure Takeda Non-Insulin Therapies for Diabetes Revenue Market Share in United States (2013-2018)
Table 3SBio Basic Information List
Table Merck Basic Information List
Table Dong-A Pharmaceutical Basic Information List
Table Luye Pharma Group Basic Information List
Table Eurofarma Basic Information List
Table Geropharm Basic Information List
Table Alkem Labs Basic Information List
Table SatRx Basic Information List
Table Pfizer Basic Information List
Table Jiangsu Hengrui Medicine Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Non-Insulin Therapies for Diabetes
Figure Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes
Figure Non-Insulin Therapies for Diabetes Industrial Chain Analysis
Table Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Players/Suppliers in 2017
Table Major Buyers of Non-Insulin Therapies for Diabetes
Table Distributors/Traders List
Figure United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Type in 2025
Table United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Application in 2025
Table United States Non-Insulin Therapies for Diabetes Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Non-Insulin Therapies for Diabetes Sales Volume Share Forecast by Region (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume Share Forecast by Region (2018-2025)
Figure United States Non-Insulin Therapies for Diabetes Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories